Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Meningococcal Disease
Interventions
BIOLOGICAL

MenACWY-CRM

Trial Locations (11)

12627

Dr med Kerstin Pscherer, Hellersdorfer Str 237, Berlin

13347

Dr med Luise Schroeter, Schoenwalder Str 28, Berlin

24534

Dr. Johannes Kandzora and Dr. Kathrin Kandzora, Am Teich 11, Neumuenster

24960

Ute Jessat, Rathausstr 6, Gluecksburg

36037

Dr med Walter Otto, Heinrichstrasse 16 A, Fulda

37269

Bogda-Maria Kniese,, Boyneburgstr 7, Eschwege

67227

Dr Lothar Maurer, Welschgasse 39, Frankenthal

70469

Dr med Ulrich Pfletschinger, Stuttgarter Strasse 74, Stuttgart Feuerbach

71720

Dr Goertz Martin Kimmig, GroBbottwarer Str 47, Oberstenfeld

74357

Dr Renate Mangelsdorf-Taxis, Kirchstrasse 2, Bonnigheim

82362

Dr. Christoph Wittermann, Murnauer Str 3, Weilheim

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT01345721 - Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine | Biotech Hunter | Biotech Hunter